Poster Abstract Session:
146. Pneumococcal Vaccines
Friday, October 5, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall

Tracks: Adult ID, Epidemiology and Infection Control, Investigative ID, Pediatric ID


Presentations:
Impact of Routine Pediatric PCV13 on the Incidence and Severity of Invasive Pneumococcal Disease in Adults in Ontario, Canada.
Sarah Nayani, PhD; Karen Green, MSc, RN; Hedan Han, MSc; Jeff Li, BSc; Agron Plevneshi, BSc; Wallis Rudnick, MSc.; Allison McGeer, MD, MSc
Modeling Reductions in Antibiotic Prescriptions due to Otitis Media in Canada as a Result of Pneumococcal Conjugate Vaccination
Marie-Claude Breton, MPharm; Raymond Farkouh, PhD; Jelena Vojicic, MD; Michele Wilson, MSPH; Cheryl McDade, BA; Matt Wasserman, MSc
Posters
  • 2018 IDWEEK_Canada AMR Poster.pdf (1021.0 kB)
  • Emergence of Multidrug Resistant Serotype 24 among Children under 2 years old with Invasive Pneumococcal Disease after the Introduction of PCV13 in Argentina
    Paula Gagetti, MD; Alejandra Menocal, MD; Diego Faccone, PhD; Sofia Fossati, MD; Daniela Napoli, MD; Mabel Regueira, MD; Argentina Spn Working, Group; Alejandra Corso, MD
    Posters
  • Gagetti ID Week 2018.pdf (1.0 MB)
  • Evolving impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease
    Inci Yildirim, MD PhD MSc; Brent A. Little, PhD; Kimberly M. Shea, PhD, MPH; Stephen I. Pelton, MD; Members Of The Department Of Public Health Massachusetts, MDPH
    County-Wide Pediatric IPD Experience Following Prevnar 13 Implementation
    Delma Nieves, MD; Stephanie Osborne, BS, RN; Michele Cheung, MD MPH; Antonio Arrieta, MD, FIDSA
    Posters
  • 1432 Nieves ID Week 2018.pdf (553.1 kB)
  • The Cost-effectiveness of Vaccinating with an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina
    Van Nguyen, Pharm.D.; Carla Vizzotti, MD; Analia Uruena, MD; Norberto Giglio, MD; Maria Cecilia Magneres, MD; Heather Richmond, MPH
    Risk Factors for Invasive Pneumococcal Disease in Adults ≥65 Years Old Following Pneumococcal Conjugate Vaccine Recommendation
    Olivia M. Almendares, MSPH; Wei Xing, MS; Monica M. Farley, MD, FIDSA; William Schaffner, MD, FIDSA, FSHEA; Ann Thomas, MD, MPH; Arthur Reingold, MD, FIDSA; Lee H. Harrison, MD; Corinne Holtzman, MPH; Jemma V. Rowlands, MPH; Susan Petit, MPH; Meghan Barnes, MSPH; Salina Torres, PhD; Bernard Beall, PhD; Cynthia Whitney, MD, MPH, FIDSA; Tamara Pilishvili, MPH, PhD
    Family Duty and Safety Linked to Overcoming Attitudinal Barriers to Adult Pneumococcal Vaccination in Disparate Populations
    Maria-Stephanie Tolg, PharmD; Marc Hutchison, Ph.D; Brian Krueger, Ph.D; Katherine Orr, PharmD; Jennifer DeAngelis, BA; Aisling Caffrey, PhD, MS; Kerry LaPlante, Pharm.D., FCCP, FIDSA
    Potential Impact of Routine Use of 13-valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada
    Jelena Vojicic, MD; Stephane Dion, PhD; Raúl E. Isturiz, MD; Craig Laferriere, PhD; Maria Major, MPH; Rajeev M. Nepal, PhD; Jose A. Suaya, MD, PhD; John M. McLaughlin, PhD
    Posters
  • Impact PCV13 on Hosp.pdf (939.1 kB)
  • Doses of 13-valent conjugated pneumococcal vaccine (PCV13) for patients with multiple myeloma (MM)
    Hsin-Yun Sun, MD; Aristine Cheng, MD; Shang-Yi Huang, M.D.; Sui-Yuan Chang, DSc; Yee-Chun Chen, M.D., Ph.D.; Shan-Chwen Chang, M.D., PhD
    Pneumonia Hospitalizations Averted with 13-valent Pneumococcal Conjugate Vaccination of Adults Aged 18-64 Years with Diabetes in The United States
    Jose Suaya, MD, PhD; Bradford D. Gessner, MD; Erica Chilson, PharmD; Jelena Vojicic, MD; David L. Swerdlow, MD; Raúl E. Isturiz, MD; John M. McLaughlin, PhD
    Posters
  • IDWeerk_diabetes_2018v10f.pdf (125.2 kB)
  • Serotypes 8 and 3 are the leading cause of invasive pneumococcal disease in adults in Portugal (2015-2017)
    Catarina Silva-Costa, PhD; Elísia Lopes, MSc; Mario Ramirez, PhD; Jose Melo-Cristino, MD, PhD
    Trends in Antimicrobial Non-susceptibility of PCV13-type Streptococcus pneumoniae Pneumonia in Adults in the United States during 2009-2017
    Rodrigo E. Mendes, Ph.D.; Jose A. Suaya, MD, PhD; Timothy B. Doyle, MS; Leah N. Woosley, B.S.; Robert K. Flamm, PhD; Bradford D. Gessner, MD; Raul E. Isturiz, MD
    Impact of 10-valent Pneumococcal Conjugate Vaccine Introduction on Pneumococcal Carriage and Antibiotic Susceptibility Patterns among Children Aged <5 Years and Adults with HIV Infection, Kenya 2009–2013
    Miwako Kobayashi, MD, MPH; Lindsay Kim, MD, MPH; Godfrey Bigogo, MPH; Daniel Ondari, BA, CM; Laura Conklin, MD; Arthur Odoyo, BS; Herine Odiembo, MPH; Fabiana Pimenta, PhD; Dominic Ouma, MPH; Aaron Harris, MD, MPH; Kennedy Odero, MA; Jennifer Milucky, MPH; Alice Ouma, MSc; George Aol, MPH; Allan Audi, MSc; Clayton Onyango, MSc; Leonard Cosmas, MPH; Geofrey Jagero, MSc; Jennifer Farrar, MPH; Maria Da Gloria Carvalho, PhD; Cynthia Whitney, MD, MPH, FIDSA; Robert F. Breiman, MD, FIDSA; Fernanda C. Lessa, MD, MPH
    Correlation between Adult Invasive and Non-Invasive Streptococcus pneumoniae Disease in 13-valent Pneumococcal Conjugate Vaccine Serotypes in the United States
    Jose A. Suaya, MD, PhD; Adriano G. Arguedas, MD; Rodrigo E. Mendes, Ph.D.; Jelena Vojicic, MD; David L. Swerdlow, MD; Raul E. Isturiz, MD; Bradford D. Gessner, MD
    Posters
  • IDWeerk_correlation_2018v8.pdf (137.4 kB)
  • CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.